Time-restricted Eating for Patients With Type 2 Diabetes
Part of paid clinical trials in Lexington, Kentucky.
- Sponsor
- Justin (Matt) Thomas
- Study ID
- NCT07318207
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Time-restricted eating — BEHAVIORALSubjects will consume all daily calories within a 10-hour (10h +/- 1hr) window during the daytime, ending by 8:00pm. Subjects will text the time of their first and last daily calorie intake for the duration of the study.
Study Details
This is a single-arm pragmatic clinical trial of time-restricted eating in patients with type 2 diabetes. Patients will be recruited from the University of Kentucky Barnstable Brown Diabetes Center. Subjects will participate in a 10-hour time-restricted eating intervention for 1-year.
Key Dates
- Start date
- Apr 30, 2026
- Status verified
- Feb 2026
- Primary completion
- Jun 30, 2027
- Completion
- Jun 30, 2027
Study Design
- Enrollment
- 102 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Time-restricted eatingSubjects in this group will consume all daily calories within a 10-h window during the day for 1-year.
Primary Outcome Measure
Change in Hemoglobin A1c [ Time Frame: At least 2 timepoints between baseline and 1 year. Since labs will depend on clinic visits, exact timeframe will vary. ]
Central Contacts
- Matt Thomas, PhD859-562-0642
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Kentucky Barnstable Brown Diabetes Center | Lexington | Kentucky | 40504 |
Find similar trials in Lexington, KY
By condition
By specialty
Related Studies
- Effectiveness and Safety of the RIGHTEST Continuous Glucose Monitoring System for Blood Glucose Management in Persons With Diabetes MellitusNot Yet Recruiting · Bionime Corporation · Guntersville, Alabama
- Military Health and Nutrition Examination StudyRecruiting · Pennington Biomedical Research Center · Fort Campbell, Kentucky
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)PHASE3 · Recruiting · Eli Lilly and Company · Tucson, Arizona
- Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)PHASE2 · Recruiting · Sparrow Pharmaceuticals · Chandler, Arizona